Expression of the potential therapeutic target claudin-18.2 is frequently decreased in gastric cancer: results from a large Caucasian cohort study
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cell Biology,Molecular Biology,General Medicine,Pathology and Forensic Medicine
Link
http://link.springer.com/content/pdf/10.1007/s00428-019-02624-7.pdf
Reference34 articles.
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca-Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492
2. Takahashi T, Saikawa Y, Kitagawa Y (2013) Gastric cancer: current status of diagnosis and treatment. Cancers (Basel) 5:48–63. https://doi.org/10.3390/cancers5010048
3. Lazar DC, Taban S, Cornianu M, Faur A, Goldis A (2016) New advances in targeted gastric cancer treatment. World J Gastroenterol 22:6776–6799. https://doi.org/10.3748/wjg.v22.i30.6776
4. Sahin U, Koslowski M, Dhaene K, Usener D, Brandenburg G, Seitz G, Huber C, Tureci O (2008) Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res 14:7624–7634. https://doi.org/10.1158/1078-0432.CCR-08-1547
5. Lordick F, Schuler MH, Al-Batran S, Zvirbule Z, Manikhas G, Rusyn AV, Vynnychenko I, Fadeeva N et al (2016) Claudin 18.2 – a novel treatment target in the multicenter, randomized, phase ii fast study, a trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-cldn18.2 antibody imab362 as 1st line therapy in advanced gastric and gastroesophageal junction (GEJ) cancer. Ann Oncol 27:ix68–ix85. https://doi.org/10.1093/annonc/mdw582
Cited by 77 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Claudin-18.2 Immunohistochemical Evaluation in Gastric and Gastroesophageal Junction Adenocarcinomas to Direct Targeted Therapy: A Practical Approach;Modern Pathology;2024-11
2. Heterogeneity of claudin 18.2 expression in metastatic gastric cancer;Scientific Reports;2024-07-31
3. Claudin18.2-Targeted SPECT/CT Imaging for Gastric Cancer: Preclinical Evaluation and Clinical Translation of the 99mTc-Labeled Nanobody (PHG102) Radiotracer;ACS Pharmacology & Translational Science;2024-07-20
4. Progress of Clinical Studies Targeting Claudin18.2 for the Treatment of Gastric Cancer;Digestive Diseases and Sciences;2024-05-20
5. Retrospective Study of Claudin 18 Isoform 2 Prevalence and Prognostic Association in Gastric and Gastroesophageal Junction Adenocarcinoma;JCO Precision Oncology;2024-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3